332,210 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Bought by Wealthfront Advisers LLC

Wealthfront Advisers LLC acquired a new position in shares of 10x Genomics, Inc. (NASDAQ:TXG) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 332,210 shares of the company’s stock, valued at approximately $4,418,000.

A number of other hedge funds have also bought and sold shares of TXG. JPMorgan Chase & Co. lifted its stake in shares of 10x Genomics by 355.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 355,488 shares of the company’s stock worth $8,027,000 after acquiring an additional 277,355 shares during the last quarter. Entropy Technologies LP boosted its position in 10x Genomics by 285.6% during the 4th quarter. Entropy Technologies LP now owns 37,595 shares of the company’s stock valued at $540,000 after acquiring an additional 27,844 shares in the last quarter. Geode Capital Management LLC boosted its position in 10x Genomics by 2.4% during the third quarter. Geode Capital Management LLC now owns 1,815,710 shares of the company’s stock valued at $41,009,000 after purchasing an additional 42,777 shares in the last quarter. SG Americas Securities LLC grew its position in shares of 10x Genomics by 209.8% in the 4th quarter. SG Americas Securities LLC now owns 73,046 shares of the company’s stock worth $1,049,000 after buying an additional 49,468 shares during the last quarter. Finally, Alberta Investment Management Corp purchased a new position in 10x Genomics in the fourth quarter worth $3,206,000. Institutional investors own 84.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on TXG shares. Weiss Ratings restated a “sell (e+)” rating on shares of 10x Genomics in a research note on Friday, March 7th. UBS Group decreased their price objective on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a report on Thursday, February 13th. Barclays lowered their price target on 10x Genomics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research report on Monday, February 10th. Morgan Stanley cut their price objective on 10x Genomics from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Finally, Leerink Partners lowered 10x Genomics from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $25.00 to $12.00 in a research report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, 10x Genomics presently has a consensus rating of “Hold” and an average price target of $20.21.

Insider Activity

In other news, Director Alan Mateo purchased 40,000 shares of 10x Genomics stock in a transaction dated Friday, February 21st. The shares were purchased at an average price of $11.14 per share, with a total value of $445,600.00. Following the transaction, the director now owns 61,691 shares in the company, valued at $687,237.74. This represents a 184.41 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Benjamin J. Hindson sold 4,573 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $50,623.11. Following the completion of the transaction, the insider now owns 335,324 shares in the company, valued at $3,712,036.68. This represents a 1.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 10.03% of the company’s stock.

10x Genomics Price Performance

TXG opened at $9.88 on Friday. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -6.50 and a beta of 1.93. The company’s 50 day simple moving average is $13.32 and its two-hundred day simple moving average is $16.10. 10x Genomics, Inc. has a 1-year low of $9.27 and a 1-year high of $39.30.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. On average, equities analysts anticipate that 10x Genomics, Inc. will post -1.43 earnings per share for the current fiscal year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.